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The survival of patients with heart failure with
preserved or reduced left ventricular ejection
fraction: an individual patient data meta-analysis
Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)
Received 18 March 2011; revised 30 May 2011; accepted 4 July 2011
Aims A substantial proportion of patients with heart failure have preserved left ventricular ejection fraction (HF-PEF). Pre-
vious studies have reported mixed results whether survival is similar to those patients with heart failure and reduced
EF (HF-REF).
Methods
and results
We compared survival in patients with HF-PEF with that in patients with HF-REF in a meta-analysis using individual
patient data. Preserved EF was defined as an EF ≥ 50%. The 31 studies included 41 972 patients: 10 347 with HF-PEF
and 31 625 with HF-REF. Compared with patients with HF-REF, those with HF-PEF were older (mean age 71 vs.
66 years), were more often women (50 vs. 28%), and have a history of hypertension (51 vs. 41%). Ischaemic aetiology
was less common (43 vs. 59%) in patients with HF-PEF. There were 121 [95% confidence interval (CI): 117, 126]
deaths per 1000 patient-years in those with HF-PEF and 141 (95% CI: 138, 144) deaths per 1000 patient-years in
those with HF-REF. Patients with HF-PEF had lower mortality than those with HF-REF (adjusted for age, gender,
aetiology, and history of hypertension, diabetes, and atrial fibrillation); hazard ratio 0.68 (95% CI: 0.64, 0.71). The
risk of death did not increase notably until EF fell below 40%.
Conclusion Patients with HF-PEF have a lower risk of death than patients with HF-REF, and this difference is seen regardless of
age, gender, and aetiology of HF. However, absolute mortality is still high in patients with HF-PEF highlighting the
need for a treatment to improve prognosis.
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Introduction
Heart failure is a leading cause of cardiovascular morbidity and
mortality and arises as a consequence of many cardiovascular con-
ditions, including coronary artery disease (CAD), valve disease, and
hypertension. Heart failure has been traditionally viewed as a
failure of contractile function and left ventricular (LV) ejection frac-
tion (EF) has been widely used to define systolic function, assess
prognosis, and select patients for therapeutic interventions.
However, it is recognized that heart failure can occur in the pres-
ence of normal or near-normal EF: so-called ‘heart failure with pre-
served EF (HF-PEF)’ which accounts for a substantial proportion of
clinical cases of heart failure.1–4
There are many differences between patients with heart failure
with reduced EF (HF-REF) and patients with HF-PEF. The latter are
older and more often women, are less likely to have CAD, and
more likely to have underlying hypertension.1,2,5 In addition,
patients with HF-PEF do not obtain similar clinical benefits from
angiotensin-converting enzyme (ACE) inhibition or angiotensin
receptor blockade compared with patients with HF-REF.6–8
Several comparisons of survival between patients with HF-PEF
and those with HF-REF have been reported but have given incon-
sistent results.1,2 Although a recent literature-based meta-analysis
demonstrated that patients with HF-PEF may have lower mortality
than those with HF-REF,9 lack of patient-level data precluded
careful adjustment for differences between these patient groups
in potentially important prognostic variables such as age, gender,
co-morbidity, and aetiology of HF.
Therefore, we undertook a meta-analysis using individual patient
data to examine mortality rates in patients with HF-PEF and HF-REF.
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Methods
A comprehensive search was undertaken for a literature-based
meta-analysis of observational studies and randomized controlled
trials (RCTs) published to the end of 2006, and the details of this
have been reported.9 The same search process was repeated to the
end of 2008. In brief, we searched online databases including
Embase, Medline, Medline In-progress, and PubMed using the key
words: prognosis, outcome, heart failure, left ventricle, and preserved.
We also searched reference lists of articles obtained during the
search and conference abstracts and made personal communication
with investigators and authors. Abstracts, unpublished studies, and
articles published in languages other than English were not excluded.
Eligible studies were those that included patients with heart failure
and reported the outcome of interest (death from any cause) and
where EF criterion was not used for entry into the study. All the indi-
vidual studies were approved by Ethics Committees. The meta-analysis
was approved by The University of Auckland Human Subjects Ethics
Committee.
Study selection and data extraction
We identified 56 potentially suitable studies: principal investigators for
each of these studies were invited to participate in this meta-analysis.
An executive group was formed to oversee the data management and
analysis, and the steering group involved the principal investigator from
each study. Investigators from 31 studies (3 pharmacotherapy RCTs, 4
management intervention RCTs, and 24 observational studies)10–40
provided individual patient data on a pre-defined set of variables
including demographics (age, sex, and ethnicity), medical history
(history of myocardial infarction, coronary revascularization, diabetes,
hypertension, stroke, lung disease, peripheral artery disease, and
smoking), medical treatment (ACE-inhibitor, angiotensin receptor
blocker, b-blocker, diuretic, and aldosterone antagonist), symptom
status [New York Heart Association (NYHA) functional class, dys-
pnoea, paroxysmal nocturnal dyspnoea, and oedema], clinical variables
(heart rate, blood pressure, and pulmonary rales), laboratory variables
(serum sodium, creatinine, and EF), and outcome (deaths and
follow-up duration). Data from 30 of the individual studies were
re-coded at the Central Coordinating Centre at the University of
Auckland into a uniform format. Data were checked and queries
resolved, and the summary data from each study compared against
the original published data prior to incorporation into a single data-
base. This data set was then sent to the London School of Hygiene
and Tropical Medicine finally where the CHARM trial data were incor-
porated to create the final data set (31 studies) within which these
analyses were undertaken.
Our primary hypothesis was that patients with HF-PEF would have a
lower mortality rate than patients with HF-REF, even after adjustment
for other prognostic variables.
Ejection fraction
In 18 studies, a preference for rounding EF to the nearest 5% was
observed. In these studies, EF at these rounded values was reallocated
within 2.5% either side of the rounded value by random selection from
a uniform distribution. For example, EF values of 20% were randomly
reallocated to values between 17.5 and 22.4%. Preserved EF was pre-
specified as EF ≥50%.
Statistical analysis
The baseline variables for the HF-PEF and HF-REF groups were com-
pared using Student’s t-test for continuous variables and the x2 tests of
proportions for categorical variables. For all analyses, the outcome was
the rate of death from any cause at 3 years from hospital discharge or
baseline study visit. Three-year death rates and deaths per 1000
patient-years were calculated. Cox’s proportional hazard models
were used to estimate the hazard of HF-PEF compared with HF-REF,
adjusted for age, gender, ischaemic aetiology, a history of hypertension,
diabetes, and atrial fibrillation, and stratified by study. These variables
chosen for the model were selected for clinical relevance and where
data were available for that variable in more than 90% of the patients
in the MAGGIC data set. Data on NYHA functional class and medi-
cations (ACE-inhibitor and/or angiotensin receptor antagonist and/or
b-blockers) were available on fewer patients in the MAGGIC data
set. However, due to the importance of these variables in relation
to outcome, the Cox proportional hazards model was repeated with
incorporation of these variables in turn into the above model. In the
whole group, within age groups and within gender, EF, 50% was
the referent; when comparing mortality across 10% bands of EF,
EF ≥ 60% was the referent. The correlation between the scaled
Schoenfeld residuals and length of follow-up showed that there was
no violation of the proportional hazards assumption for all analyses.
Mortality curves were created of adjusted models that were not stra-
tified by study. Analyses were performed using R version 2.9.0.41
Results
Thirty one of the 56 identified studies contributed data on 54 416
patients (Figure 1). One thousand one hundred and seventy-nine
patients were excluded due to irresolvable dates or death during
an index hospital admission and 2246 excluded as heart failure
was secondary to severe valvular heart disease or hypertrophic
cardiomyopathy. Ejection fraction data were not available for
9019 patients, and thus the main analysis was based on 41 972
patients for whom EF data were available. Ejection fraction was
assessed using echocardiography in 33 717 (80.4%), scintigraphy
in 6899 (16.4%), and angiography in 1356 (3.2%). Quantitative EF
data were available for 38 484 (92%) patients and the remainder
(3488, 8%) had semi-quantitative EF assessment: 10 347 (24.7%)
patients had HF-PEF and 31 625 (75.3%) had HF-REF. The baseline
Figure 1 Flow chart of studies for meta-analysis.
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characteristics are shown in Table 1. When compared with the
HF-REF patients, those with HF-PEF were older (mean age
71 years SD 12 vs. 66 years SD 12), were more often women (50
vs. 28%), more often had a history of hypertension (51 vs. 41%)
and atrial fibrillation (27 vs. 18%), and less often ischaemic aetiol-
ogy (43 vs. 59%). Patients with HF-REF were more commonly
receiving treatment with an ACE-inhibitor (75 vs. 44%),
b-blocker (39 vs. 33%), and spironolactone (24 vs. 16%) compared
with those with HF-PEF. For the 25 studies for which patient data
were not available, the weighted mean from published data
showed that these patients were slightly older (mean age
71 years), fewer were women (34%), and the proportion of
patients with missing EF was higher (33%) than the included
studies.
The median duration of follow-up for patients with a missing EF
was only 121 days [inter-quartile range (IQR) 85, 365] compared
with those with an available EF: HF-PEF group 1024 (IQR 246,
1546) days and HF-REF group 933 (IQR 346, 1348) days. Due to
the large difference in duration of follow-up, the group with
missing EF was not considered further in this analysis. The primary
outcome of death from any cause occurred in 2422 (23.4%) patients
with HF-PEF and in 8332 (26.3%) in those with HF-REF. There were
121 [95% confidence interval (CI): 117, 126] deaths per 1000
patient-years in those with HF-PEF and 141 (95% CI: 138, 144)
deaths per 1000 patient-years in those with HF-REF. In univariate
analysis, patients with HF-PEF were at lower risk of death than
those with HF-REF, hazard ratio (HR) 0.71 (95% CI: 0.67, 0.74). In
the adjusted Cox proportional hazards model, patients with
HF-PEF had lower mortality than those with HF-REF, adjusted HR
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Table 1 Baseline characteristics of the groups
Whole group HF-PEF HF-REF Missing LVEF P-value (HF-PEF vs. HF-REF)
n (31 studies) 50 991 10 347 31 625 9019 —
Age [years (SD)] 68 (12) 71 (12) 66 (12) 71 (13) ,0.001
Women (%) 35% 50% 28% 44% ,0.001
Medical history
Hypertension 43% 51% 41% 40% ,0.001
Myocardial infarction 43% 27% 51% 31% ,0.001
Atrial fibrillation 21% 27% 18% 23% ,0.001
Diabetes 23% 23% 24% 21% 0.005
Ischaemic aetiology 54% 43% 59% 49% ,0.001
Medication
ACE-inhibitor or ARB 67% 44% 75% 64% ,0.001
b-Blocker 34% 33% 39% 23% ,0.001
Diuretic 82% 78% 83% 83% ,0.001
Spironolactone 21% 16% 24% 17% ,0.001
Digoxin 43% 32% 47% 44% ,0.001
Clinical status
NYHA class (I/II/III/IV) (%) 11/47/34/8 14/48/29/9 10/46/37/7 19/48/25/8 All ,0.004
Heart rate (b.p.m.) 79 (18) 78 (21) 79 (18) 79 (17) 0.019
SBP (mmHg) 131 (23) 141 (25) 128 (22) 135 (24) ,0.001
DBP (mmHg) 77 (13) 79 (14) 76 (12) 80 (13) ,0.001
LVEF % (median, IQR) 36 (27, 48) 60 (55, 61) 31 (24, 39) — —
Values represent mean (standard deviation) unless stated. ARB, angiotensin receptor blocker; IQR, inter-quartile range; NYHA, New York Heart Association functional class;
LVEF, left ventricular ejection fraction.
Figure 2 Mortality for patients with HF-PEF (heart failure with
preserved left ventricular ejection fraction) and HF-REF (heart
failure with low left ventricular ejection fraction), adjusted for
age, gender, aetiology of heart failure, hypertension, diabetes,
atrial fibrillation.
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0.68 (95% CI: 0.64, 0.71; Figure 2 and Table 2). When the RCTs of
pharmacotherapy (three trials, 20 878 patients) were excluded
from the analysis, there were 146 (95% CI: 138, 154) deaths per
1000 patient-years in those with HF-PEF and 159 (95% CI: 154,
165) deaths per 1000 patient-years in those with HF-REF, and the
risk of death remained lower in the patients with HF-PEF compared
with those with the HF-REF group: adjusted HR 0.76 (95% CI: 0.71,
0.82). Correspondingly, in the randomized trials alone, there were
101 (95% CI: 96, 107) deaths per 1000 patient-years in those with
HF-PEF and 131 (95% CI: 127, 134) deaths per 1000 patient-years
in those with HF-REF and the risk of death remained lower in the
patients with HF-PEF compared with those with HF-REF, adjusted
HR 0.61 [95% CI: 0.57, 0.65; interaction EF × study design (RCT
or non-RCT), P ¼ 0.0007]. For studies that recruited patients who
were hospitalized at baseline (n ¼ 18 108), the adjusted HR for
death from any cause for patients with HF-PEF compared with
those with HF-REF was 0.70 (95% CI: 0.66, 0.74) and was 0.59
(95% CI: 0.54, 0.66) for studies involving patients who were not
hospitalized (n ¼ 20 213). Thus, irrespective of whether hospital-
ized or not, patients with HF-PEF had a lower risk of death than
patients with HF-REF. However, this difference appeared to be
greater in ambulatory than in hospitalized patients.
Data on cardiovascular death were available for 26 725 patients
from 14 studies; in an adjusted Cox proportional hazards model,
patients with HF-PEF had lower risk of cardiovascular death than
those with HF-REF, adjusted HR 0.55 (95% CI: 0.49, 0.61;
Table 2). When the adjusted Cox proportional hazards model
was repeated with inclusion of either NYHA functional class
(16 592 patients) or medications (11 908 patients), similar results
were seen for both death from any cause and cardiovascular
death: NYHA included in model HR for death from any cause
0.68 (95% CI: 0.60, 0.77) and for cardiovascular death HR 0.62
(95% CI: 0.52, 0.75); medications included in model HR for
death from any cause 0.66 (95% CI: 0.62, 0.69) and for cardiovas-
cular death HR 0.47 (95% CI: 0.33, 0.68).
Risk of death from any cause and cardiovascular death by EF cat-
egory is shown in Figure 3. The HR for death in patients with an EF
50–59% and in those with an EF between 40 and 49% was not
increased compared with patients with an EF of 60% or above.
However, the HR for death increased steadily below an EF of
40%. The rate of death increased with age: 847 (12.8%) deaths
among 6624 patients aged ,55 years, 5617 (21.7%) deaths
among 25 882 patients aged 55–75 years, and 5510 (36.0%)
deaths among 15 280 patients aged .75 years. In all three age
groups, patients with HF-PEF had a lower risk of death than
patients with HF-REF, with no differences in HR for men and
women (Figure 4). There was no interaction between gender and
age for death from any cause (P ¼ 0.604). However, the HR for
the difference in mortality between patients with HF-PEF and
those with HF-REF appeared to differ according to age (age/EF
group interaction, P, 0.0001). For example, for women aged
≥75 years, the adjusted HR comparing risk of death among
women with HF-PEF and those with HF-REF was 0.79 (95% CI:
0.72, 0.87) compared with 0.38 (95% CI: 0.22, 0.65) for women
aged ,55 years. Similarly, for men aged ≥75 years, the adjusted
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Cox’s proportional adjusted hazards ratios
for all-cause death and cardiovascular death
Variable Death from any
cause
Cardiovascular
death
Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
HF-PEF 0.68 (0.64, 0.71) 0.55 (0.49, 0.61)
Male gender 1.23 (1.18, 1.28) 1.23 (1.14, 1.33)
Age (years) 1.04 (1.04, 1.04) 1.03 (1.03, 1.04)
Ischaemic
aetiology
1.07 (1.02, 1.12) 1.11 (1.03, 1.19)
Hypertension 0.93 (0.89, 0.97) 0.94 (0.88, 1.00)
Diabetes 1.41 (1.35, 1.47) 1.51 (1.41, 1.62)
Atrial fibrillation 1.10 (1.05, 1.16) 1.28 (1.16, 1.41)
Figure 3 Adjusted hazard ratios comparing death from any cause and cardiovascular death by groups of left ventricular ejection fraction (with
LVEF ≥ 60% as the reference group).
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HR comparing risk of death among men with HF-PEF and those
with HF-REF was 0.74 (95% CI: 0.67, 0.81) compared with 0.50
(95% CI: 0.37, 0.69) for men aged ,55 years. This indicates that
the difference in the risk of death among patients with HF-PEF
and HF-REF was less among older patients than in younger
patients.
Discussion
This large systematic review of over 40 000 patients evaluating the
survival of patients with HF-PEF or HF-REF has three principal find-
ings. First, patients with HF-PEF had a 32% lower risk of death over
3 years compared with those with HF-REF. Secondly, the pheno-
type of patients in this study with HF-PEF confirms early studies
demonstrating striking gender and age differences between the
two syndromes. Compared with those with HF-REF, patients
with HF-PEF were typically 5 years older, half were women but
were less likely to have ischaemic heart disease as the aetiology
of their heart failure. Thirdly, even after adjusting for these and
other prognostic variables using individual patient data in this
meta-analysis, the difference in mortality remained in both men
and women and was present irrespective of aetiology of heart
failure and age. Similar results were also observed whether the
patients were hospitalized or not at baseline and whether involved
in RCTs of pharmacotherapy or observational studies. These
results, obtained by analysing more than 10 000 deaths among
more than 40 000 patients, provide clear evidence that survival is
different for these two distinct phenotypes of the heart failure
syndrome.
While a number of studies have reported on outcome for
patients with HF-PEF compared with those with HF-REF, the indi-
vidual results have been conflicting. Two large retrospective
community-based studies reported that mortality was similar for
patients with HF-PEF and HF-REF.1,2 Several sources of bias exist
in studies reporting outcome, for example, ideally any such study
for patients with heart failure utilizing a cut-off of EF would have
EF measurements available for all patients, although this is rarely
the case. If missing EF measurements were to occur across all
patient groups, then this would not introduce bias. However, EF
measurement is undertaken less frequently in some patient
groups such as the elderly42 and patients with missing EF measure-
ment have worse outcome than those with EF measurements.43
Consequently, exclusion of patients due to missing EF measure-
ments can introduce systematic bias. While the current
meta-analysis was not able to obtain individual patient data from
all prior studies, the proportion of patients missing EF data was
only 18% from the studies providing data, while the studies not
contributing data had EF missing in 42% of the patients, thus the
potential effects of missing EF data are likely to be lessened in
the current analyses.
Characterization of patients with HF-PEF has been hampered by
lack of a consistent definition of this condition. Earlier recommen-
dations advocating the application of detailed assessment of LV dias-
tolic functionwere complicated and effectively unworkable in clinical
practice.44 Furthermore, diastolic dysfunction is unlikely to be the
sole underlying cardiac abnormality in all such patients, and other
factors, such as atrial fibrillation, valve disease, andmyocardial ischae-
mia, as well as non-cardiac conditions such as renal impairment,
anaemia, obesity, and diabetes, are likely to contribute. A simple
approach, as used in this currentmeta-analysis, is to define this symp-
tomatic group of patients by an EF cut-off. This is attractive in that EF
is commonly utilized in clinical practice to guide application of
evidence-based therapies.45 However, this approach is effectively
one of ‘exclusion’ and likely results in a heterogeneous group of
patients with multiple underlying cardiac abnormalities contributing
to the heart failure despite preserved EF, including some with subtle
abnormalities of LV systolic function.46–48 In addition, there has been
concern that with this approach patients with non-cardiac causes of
breathlessness, exercise intolerance, and oedema may erroneously
be labelled as having heart failure.49
Furthermore, the optimal EF cut-off for the simple classification
of heart failure (HF-PEF or HF-REF) remains uncertain. Our data
demonstrate that mortality risk does not increase substantially
until EF falls below 40%, consistent with prior arbitrary use of
this cut-point in trials of pharmacological treatment. More recently,
recommendations have been made to incorporate LV size, and
other echocardiographic and neurohormonal variables in this defi-
nition,50 although these remain to be prospectively evaluated in
large groups of patients with heart failure.
The current data are based on a large group of patients for
whom one measurement of EF was available at the baseline assess-
ment, which was used to define the group of patients with pre-
served or reduced EF. Prior studies suggest that EF
measurements are similar whether obtained at the time of acute
heart failure decompensation or at a later time when compensated
and symptoms improved.51 However, it remains uncertain whether
the group of patients with HF-PEF will develop progressive wor-
sening of EF in the longer-term as their disease progresses in
association with subsequent events, although there are some
data to suggest that patients with HF-PEF may only develop pro-
gressive LV remodelling if inter-current myocardial infarction
occurs.52 As a result, for some patients, the clinical outcomes
Figure 4 Adjusted hazard ratios comparing death from any
cause for patients with heart failure-preserved ejection fraction
and heart failure-reduced ejection fraction by age group.
Outcome for patients with HF and preserved LVEF Page 5 of 8
 by guest on August 7, 2011
e
u
rheartj.oxfordjournals.org
D
ow
nloaded from
 
may be influenced by progressive LV remodelling, and in others
may be influenced by vascular or other effects. Much remains to
be learned as to why some patients with similar co-morbid con-
ditions develop progressive remodelling, whereas others have
worsened diastolic function.
The extensive study of patients with HF-REF has developed an
understanding of the importance of mechanisms of death among
patients with heart failure. In particular, the relative contributions
of sudden death or death due to progressive heart failure have
become of particular importance in the era of device-based thera-
pies.53 While it is now clear that patients with HF-PEF have lower
total mortality than those with HF-REF, understanding the mode of
death among patients with HF-PEF is of importance. Recent phar-
macotherapy trials have reported that cardiovascular deaths
account for 60% of all deaths in those with HF-PEF, with sudden
death and death due to progressive heart failure appearing to be
less common among patients with HF-PEF compared with those
with HF-REF.54–56 Community-based observational studies may
involve older patients with a wider range of co-morbidities than
patients in RCTs, and this may contribute to the lower proportion
of cardiovascular deaths (49%) reported in these studies.57,58 The
difference in mortality between patients with HF-PEF and HF-REF
in the current meta-analysis was less pronounced with more
advanced age which would be consistent with a greater influence
of non-cardiovascular deaths among older patients. Further under-
standing of the mode of death in a wide range of patients with
HF-PEF will further assist with the development of appropriate
strategies to improve outcome for these patients.
Our meta-analysis has some limitations. While we combined the
data from a large number of studies and individual patients, their
value is still determined by the underlying limitations of the original
individual studies. However, incorporating data from both random-
ized trials and observational studies, resulting in a wide range of
patients, with long follow-up and a large number of clinical
events, the results are likely to be an accurate reflection of patients
commonly seen in clinical practice with the syndrome of heart
failure. Data were only incorporated from studies that enrolled
patients without an EF inclusion criterion at baseline; thus,
studies such as I-PRESERVE and PEP-CHF and the numerous indi-
vidual studies of patients with HF-REF were not included in this
meta-analysis. Data on clinical, echocardiographic, and laboratory
variables were not universally available in all studies. The variables
incorporated into the Cox proportional hazards model were
selected for clinical relevance and being available in the majority
of patients. Other variables which may have prognostic importance
were not selected due to the amount of missing data. A relatively
low proportion of the patients with HF-REF were receiving
b-blockers and spironolactone, which may reflect the time that
the studies were conducted, and could influence the overall differ-
ence in mortality seen in this analysis.
In summary, in combining individual patient data from multiple
studies, we have demonstrated that patients with HF-PEF have
lower total mortality when compared with patients with HF-REF.
In particular, risk of death appears to increase in patients with EF
below 40%. Further detailed study is required of outcome in
patients with HF-PEF to determine new therapeutic strategies to
improve outcome for these patients.
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